×
About 74,540 results

ALLMedicine™ Hepatocellular Carcinoma Center

Research & Reviews  26,027 results

Emerging insights on immunotherapy in liver cancer.
https://doi.org/10.1089/ars.2022.0047
Antioxidants & Redox Signaling; Zhang Y, Zhang X et. al.

Jun 28th, 2022 - Hepatocellular carcinoma (HCC) is a liver malignancy with high mortality rate, limited treatment options and poor prognosis. Sorafenib has been the only systemic treatment option for patients with advanced HCC for more than a decade. While HCC is ...

Liquid Biopsy Derived Circulating Tumor Cells and Circulating Tumor DNA as Novel Biomar...
https://doi.org/10.1080/14737159.2022.2094706
Expert Review of Molecular Diagnostics; Temraz S, Nasr R et. al.

Jun 28th, 2022 - The diagnosis of hepatocellular carcinoma (HCC) is made at a relatively advanced stage resulting in poor prognosis. Alpha-fetoprotein and liver ultrasound have limited accuracy as biomarkers in HCC. Liver biopsy provides information on tumor biolo...

The small GTPase RAB10 regulates endosomal recycling of the LDL receptor and transferri...
https://doi.org/10.1016/j.jlr.2022.100248
Journal of Lipid Research; Khan TG, Ginsburg D et. al.

Jun 27th, 2022 - The low-density lipoprotein receptor (LDLR) mediates the hepatic uptake of circulating low-density lipoproteins (LDL), a process that modulates the development of atherosclerotic cardiovascular disease. We recently identified RAB10, encoding a sma...

see more →

Guidelines  37 results

EASL Clinical Practice Guidelines on haemochromatosis.
https://doi.org/10.1016/j.jhep.2022.03.033
Journal of Hepatology; ,

Jun 7th, 2022 - Haemochromatosis is characterised by elevated transferrin saturation (TSAT) and progressive iron loading that mainly affects the liver. Early diagnosis and treatment by phlebotomy can prevent cirrhosis, hepatocellular carcinoma, diabetes, arthropa...

AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma.
https://doi.org/10.1053/j.gastro.2021.12.276
Gastroenterology Su GL, Altayar O et. al.

Feb 26th, 2022 - Hepatocellular carcinoma (HCC), the most common primary liver cancer, remains a deadly cancer, with an incidence that has tripled in the United States since 1980. In recent years, new systemic therapies for HCC have been approved and a critical as...

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the ...
https://doi.org/10.1016/j.numecd.2021.04.028
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; , et. al.

Dec 21st, 2021 - Nonalcoholic fatty liver disease (NAFLD) is a common and emerging liver disease in adults, paralleling the epidemic of obesity and diabetes, and leading to worrisome events (hepatocellular carcinoma and end-stage liver disease). In the last years,...

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123074
Eating and Weight Disorders : EWD;

Dec 17th, 2021 - Nonalcoholic fatty liver disease (NAFLD) is a common and emerging liver disease in adults, paralleling the epidemic of obesity and diabetes and leading to worrisome events (hepatocellular carcinoma and end-stage liver disease). In the past years, ...

External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice G...
https://doi.org/10.1016/j.prro.2021.09.004
Practical Radiation Oncology; Apisarnthanarax S, Barry A et. al.

Oct 25th, 2021 - This guideline provides evidence-based recommendations for the indications and technique-dose of external beam radiation therapy (EBRT) in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC). The American Society for Radiation...

see more →

Drugs  22 results see all →

Clinicaltrials.gov  2,195 results

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
https://clinicaltrials.gov/ct2/show/NCT04976634

Jun 24th, 2022 - The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocar...

Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B
https://clinicaltrials.gov/ct2/show/NCT01581554

Jun 24th, 2022 - Chronic hepatitis B affects at least 1.5 million Americans and is a major cause of cirrhosis, end-stage liver disease and hepatocellular carcinoma. Five oral antiviral agents have been licensed for use in chronic hepatitis B in the United States. ...

National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
https://clinicaltrials.gov/ct2/show/NCT04145141

Jun 24th, 2022 - Background: Primary liver cancer (PLC) is the 2nd most common cause of cancer-related death worldwide and the one cancer with the fastest rising incidence and mortality in the U.S. PLC consists of two main histological subtypes, i.e., hepatocellul...

Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies
https://clinicaltrials.gov/ct2/show/NCT04258566

Jun 24th, 2022 - Pilot study to evaluate the combination of optical molecular imaging (OMI) and EM tracking in localizing intrahepatic lesions and assess the concordance between fluorescence ICG and histopathology for the diagnosis of liver cancer. Hepatocellular ...

Evaluation of Patients With Liver Disease
https://clinicaltrials.gov/ct2/show/NCT00001971

Jun 24th, 2022 - This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various l...

see more →

News  1,531 results

Microwave ablation bridges patients with HCC to liver transplant
https://www.mdedge.com/gihepnews/article/255715/hepatocellular-carcinoma/microwave-ablation-bridges-patients-hcc-liver

Jun 23rd, 2022 - Key clinical point: Microwave ablation may be a safe and effective first-line locoregional therapy (LRT) for bridging patients with hepatocellular carcinoma (HCC) to liver transplant (LT), with no cases of waitlist removal due to tumor seeding, pr.

Pediatric HCC: Histologic subtypes demonstrate distinct clinical patterns
https://www.mdedge.com/gihepnews/article/255714/hepatocellular-carcinoma/pediatric-hcc-histologic-subtypes-demonstrate

Jun 23rd, 2022 - Key clinical point: The pediatric hepatocellular carcinoma (HCC) subtypes fibrolamellar carcinoma (FLC) and conventional HCC (cHCC) can be considered nonequivalent entities because they show different anatomic patterns and outcomes together with t.

SBRT plus TACE better than monotherapy in HCC with portal vein tumor thrombus
https://www.mdedge.com/fedprac/article/255712/hepatocellular-carcinoma/sbrt-plus-tace-better-monotherapy-hcc-portal-vein

Jun 23rd, 2022 - Key clinical point: Stereotactic body radiotherapy (SBRT) plus transcatheter arterial chemoembolization (TACE) may be safe and more effective than either of the procedures alone (monotherapy) for treating inoperable hepatocellular carcinoma (HCC).

Unresectable HCC: Differential efficacy of atezolizumab plus bevacizumab according to hepatic function grade
https://www.mdedge.com/fedprac/article/255711/hepatocellular-carcinoma/unresectable-hcc-differential-efficacy-atezolizumab

Jun 23rd, 2022 - Key clinical point: Atezolizumab plus bevacizumab (Atez/Bev) shows potent therapeutic efficacy against unresectable hepatocellular carcinoma (uHCC) in patients with a good hepatic function, classified as Child-Pugh A (CP-A), but has decreased effi.

Atezolizumab plus bevacizumab offers a better prognosis than lenvatinib in unresectable HCC
https://www.mdedge.com/fedprac/article/255710/hepatocellular-carcinoma/atezolizumab-plus-bevacizumab-offers-better

Jun 23rd, 2022 - Key clinical point: Therapy with atezolizumab plus bevacizumab (Atez/Bev) vs. lenvatinib in the first-line setting may confer a survival benefit in patients with unresectable hepatocellular carcinoma (uHCC).

see more →

Patient Education  4 results see all →